MX386162B - Solución oftálmica que comprende diquafosol, método para producir la misma, y método para inhibir la formación de precipitado insoluble. - Google Patents

Solución oftálmica que comprende diquafosol, método para producir la misma, y método para inhibir la formación de precipitado insoluble.

Info

Publication number
MX386162B
MX386162B MX2017010467A MX2017010467A MX386162B MX 386162 B MX386162 B MX 386162B MX 2017010467 A MX2017010467 A MX 2017010467A MX 2017010467 A MX2017010467 A MX 2017010467A MX 386162 B MX386162 B MX 386162B
Authority
MX
Mexico
Prior art keywords
ophthalmic solution
formation
diquafosol
insoluble precipitate
solution containing
Prior art date
Application number
MX2017010467A
Other languages
English (en)
Inventor
Akiko Sakatani
Koji Inagaki
Masaki Sonoda
Mitsuaki Kuwano
Tatsuo Ikei
Yoko Fukui
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of MX386162B publication Critical patent/MX386162B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Con respecto a solución oftálmica de Diquafosol que comprende un agente quelante, se ha inhibido la formación de precipitados insolubles encontrada en solución oftálmica de Diquafosol durante su almacenamiento, así como el deterioro del desempeño en filtración en el curso de producción (esterilización por filtración). Además, en la solución oftálmica de Diquafosol que comprende un agente quelante, se ha confirmado la mejora de la eficacia conservadora. En consecuencia, la presente invención proporciona UNA solución oftálmica de Diquafosol que tiene propiedades fisioquímicas que son estables durante los cursos de producción y distribución así como el curso de almacenamiento por un paciente. Particularmente en el curso de producción, la solución se puede someter a esterilización por filtración eficiente. Por otra parte, la solución tiene excelente eficacia conservadora. La presente invención también proporciona un método para inhibir la formación de precipitados insolubles de una solución oftálmica acuosa que comprende diquafosol o una sal de los mismos, al agregar un agente quelante a la solución.
MX2017010467A 2010-12-28 2011-12-27 Solución oftálmica que comprende diquafosol, método para producir la misma, y método para inhibir la formación de precipitado insoluble. MX386162B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010291463 2010-12-28
PCT/JP2011/080179 WO2012090994A1 (ja) 2010-12-28 2011-12-27 ジクアホソル含有点眼液およびその製造方法、不溶性析出物発生の抑制方法

Publications (1)

Publication Number Publication Date
MX386162B true MX386162B (es) 2025-03-18

Family

ID=46383087

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017010467A MX386162B (es) 2010-12-28 2011-12-27 Solución oftálmica que comprende diquafosol, método para producir la misma, y método para inhibir la formación de precipitado insoluble.
MX2013007502A MX2013007502A (es) 2010-12-28 2011-12-27 Solucion oftalmica que comprende diquafosol, metodo para producir la misma, y metodo para inhibir la formacion de precipitado insoluble.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013007502A MX2013007502A (es) 2010-12-28 2011-12-27 Solucion oftalmica que comprende diquafosol, metodo para producir la misma, y metodo para inhibir la formacion de precipitado insoluble.

Country Status (17)

Country Link
US (1) US20140221306A1 (es)
EP (1) EP2659894A4 (es)
JP (1) JP2012149057A (es)
KR (1) KR20140003493A (es)
CN (1) CN103282039A (es)
AU (1) AU2011350762B2 (es)
BR (1) BR112013016008B1 (es)
CA (1) CA2823148A1 (es)
EA (1) EA027736B1 (es)
GE (1) GEP20166448B (es)
MX (2) MX386162B (es)
MY (1) MY161032A (es)
PH (1) PH12013501305A1 (es)
SG (2) SG191389A1 (es)
TW (1) TW201306844A (es)
UA (1) UA113839C2 (es)
WO (1) WO2012090994A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201405799TA (en) * 2012-03-26 2014-11-27 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol
TWI709405B (zh) * 2014-12-25 2020-11-11 日商參天製藥股份有限公司 水性點眼液及其應用
KR20180014768A (ko) 2015-06-05 2018-02-09 산텐 세이야꾸 가부시키가이샤 소프트 콘택트렌즈가 착용된 드라이아이 환자의 눈에 점안되도록 이용되는 것을 특징으로 하는 드라이아이 치료제
US20210000844A1 (en) * 2018-02-28 2021-01-07 Santen Pharmaceutical Co., Ltd. Ophthalmic composition comprising diquafosol and cationic polymer
CN108853016A (zh) * 2018-09-26 2018-11-23 广州大光制药有限公司 一种地夸磷索钠滴眼液及其制备方法
JP7526718B2 (ja) * 2019-02-27 2024-08-01 参天製薬株式会社 ジクアホソルまたはその塩、ビニル系高分子およびセルロース系高分子を含有する眼科用組成物
CN114286670B (zh) * 2019-08-27 2024-01-16 参天制药株式会社 含有地夸磷索或其盐、及聚乙烯吡咯烷酮的水性眼科用组合物
JP7230169B2 (ja) * 2020-12-25 2023-02-28 参天製薬株式会社 ジクアホソルまたはその塩、銀塩およびイオン性等張化剤を含有する水性点眼液
CN113712910A (zh) * 2021-08-05 2021-11-30 广州市桐晖药业有限公司 一种滴眼液及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
DK1012154T3 (da) 1997-07-25 2004-07-26 Inspire Pharmaceuticals Inc Salte af di(uridin-5'-tetraphosphat), fremgangsmåde til fremstilling og anvendelser deraf
JP4003008B2 (ja) * 2000-05-30 2007-11-07 参天製薬株式会社 角膜上皮伸展促進剤
KR100832821B1 (ko) * 2000-05-30 2008-05-28 산텐 세이야꾸 가부시키가이샤 각막 상피 신장 촉진제
JP2003160491A (ja) * 2001-09-11 2003-06-03 Santen Pharmaceut Co Ltd ジウリジンリン酸含有点眼液
JP4168071B2 (ja) 2005-12-08 2008-10-22 興和株式会社 点眼用組成物
AU2011299851A1 (en) * 2010-09-10 2013-04-04 Santen Pharmaceutical Co., Ltd. Agent for treatment of dry eye characterized by combining P2Y2 receptor agonist with hyaluronic acid or salt thereof, method for treating dry eye, and use of the P2Y2 receptor agonist and hyaluronic acid or salt thereof

Also Published As

Publication number Publication date
MX2013007502A (es) 2013-08-01
KR20140003493A (ko) 2014-01-09
SG191389A1 (en) 2013-07-31
UA113839C2 (xx) 2017-03-27
SG10201508591UA (en) 2015-11-27
US20140221306A1 (en) 2014-08-07
EA027736B1 (ru) 2017-08-31
BR112013016008B1 (pt) 2021-06-29
EP2659894A1 (en) 2013-11-06
WO2012090994A1 (ja) 2012-07-05
JP2012149057A (ja) 2012-08-09
TW201306844A (zh) 2013-02-16
MY161032A (en) 2017-04-03
AU2011350762B2 (en) 2017-04-06
EP2659894A4 (en) 2014-12-10
BR112013016008A2 (pt) 2018-07-10
CN103282039A (zh) 2013-09-04
GEP20166448B (en) 2016-03-25
EA201390985A1 (ru) 2013-11-29
CA2823148A1 (en) 2012-07-05
PH12013501305A1 (en) 2013-08-28
AU2011350762A1 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
MX386162B (es) Solución oftálmica que comprende diquafosol, método para producir la misma, y método para inhibir la formación de precipitado insoluble.
EP4218759A3 (en) Combination therapy
UA113981C2 (xx) Офтальмологічний розчин, що містить диквафасол
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
PH12014502396B1 (en) Nitrogenated heterocyclic compound
PH12015501316A1 (en) Heterocyclic compound
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
PH12013500449A1 (en) Treatment of diseases
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
UA115133C2 (uk) Сполуки 1-арилкарбоніл-4-оксипіперидину, придатні для лікування нейродегенеративних захворювань
TN2012000401A1 (en) Heterocyclic compound
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
MX388849B (es) Derivados de heteroarilpiperidina y de heteroarilpiperazina como fungicidas.
MX348977B (es) Preparación de sales de guanidina bicíclica en un medio acuoso.
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
PH12014501711A1 (en) Benzyl sulfonamide derivatives useful as mogat-2 inhibitors
BR112015029504A2 (pt) inibidores quinase
MX2009007265A (es) Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion.
NZ700356A (en) Pyrazole compounds as sglt1 inhibitors
EA201491878A1 (ru) Замещенные ксантиновые производные
MX2012000680A (es) Sal de citrato de 9e-15-(2-pirrolidin-1-il-etoxi)-7,12,25-trioxa-1 9,21,24-triaza-tetraciclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2 ,4,9,14,16,18(26),20,22-nonaeno.
UA111145C2 (uk) Фармацевтична композиція
WO2009142968A3 (en) Valproic acid salts
TH145227A (th) เกลือ 9e-15-(2-ไพร์โรลิดิน-1-อิล-เอทอกซี่)-7,12,25-ไตรออกซะ-19,21,24-ไตรอะซา-เตตระไซโคล[18.3.1.1(2,5).1(14,18)]เฮกซะโคซา-1(24),2,4,9,14,16,18(26),20,22-โนนาอีนซิเตรท